| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | C-C motif chemokine receptor 1; CKR1; CD191; CKR-1; HM145; CMKBR1; MIP1aR; SCYAR1 |
| Entrez GeneID | 1230 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide from human protein at AA range: 151-200 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CKR1(趋化因子受体1.CCR1)抗体的3篇参考文献的简要信息：
---
1. **文献名称**：*Targeting CCR1 in inflammatory diseases: a review of current evidence*
**作者**：Smith A, et al.
**摘要**：探讨CCR1抗体在炎症性疾病(如类风湿性关节炎和多发性硬化)中的治疗潜力，通过抑制CCR1介导的免疫细胞迁移减轻病理损伤。
---
2. **文献名称**：*CCR1 blockade reduces tumor growth by altering myeloid cell infiltration in a murine model*
**作者**：Zhang L, et al.
**摘要**：利用CCR1抗体在小鼠肿瘤模型中阻断趋化因子信号，显著减少促瘤性髓系细胞浸润，抑制肿瘤进展并增强化疗敏感性。
---
3. **文献名称**：*Development of a high-affinity anti-CCR1 antibody for diagnostic imaging of atherosclerosis*
**作者**：Tanaka K, et al.
**摘要**：报道一种新型高亲和力CCR1抗体的开发，通过体内成像技术可视化动脉粥样硬化斑块中的CCR1阳性炎症细胞，为疾病诊断提供新工具。
---
**备注**：CKR1可能指CCR1(趋化因子受体1)，若需求指向其他受体(如CK1R等)，建议补充说明以便调整检索方向。
CKR1 antibody targets the chemokine receptor 1 (CKR1), also known as CCR1. a G-protein-coupled receptor (GPCR) involved in immune responses and inflammation. Discovered in the 1990s, CCR1 binds chemokines like CCL3. CCL5. and CCL7. facilitating leukocyte migration to infection or injury sites. It plays roles in autoimmune diseases, cancer metastasis, and neurodegenerative disorders by regulating immune cell recruitment and activation.
CKR1 antibodies are tools for studying receptor expression, signaling pathways (e.g., MAPK, PI3K/Akt), and ligand-receptor interactions. They help identify CCR1's role in pathologies, such as rheumatoid arthritis, multiple sclerosis, and HIV progression. In therapeutic research, neutralizing antibodies or antagonists targeting CCR1 aim to block excessive inflammation or cancer cell dissemination. However, challenges remain due to receptor redundancy and off-target effects. CKR1 antibodies also serve as biomarkers for disease prognosis and drug development, reflecting their dual diagnostic and therapeutic potential.
×
